Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Ulcerative Colitis
NCT05610956Phase 1Recruiting
- Sponsor
- Tanta University
- Start
- Jan 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in ulcerative colitis (UC) comparing Empagliflozin Group with Placebo Group (2 arms). Primary endpoint: Clinical improvement using the Montreal classification of severity of ulcerative colitis at 4 months. Started Jan 2023; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05610956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05610956.